Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 2800 participants.

Also called NCT02093845

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,800 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02093845
Other papers using this trial's data
  • Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial) JACC. Cardiovascular interventions, 2019-04-08 DOI, PubMed 30947936

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02093845. Randomized; no masking; primary purpose treatment. Start 2014-02-10 (actual); primary completion 2015-08-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII
Acronym
SORT-OUT VIII
Condition
Ischemic Heart Disease
Intervention (Device)
Biomatrix NeoFlex coronary stent
Intervention (Device)
SYNERGY stent
Lead sponsor
Aarhus University Hospital Skejby (class: other)
Collaborator
Boston Scientific Corporation (class: industry)
Collaborator
Biosensors Europe SA (class: industry)

Record details

Record id
cardio:ct-nct02093845
Content hash
a3412306ab4c9d62984c332bbc41e2f69108a266621d07f8442773d690b29b9c